A phase III study comparing nab-paclitaxel with docetaxel in patients with previously treated advanced non-small-cell lung cancer

A phase III study comparing nab-paclitaxel with docetaxel in patients with previously treated advanced non-small-cell lung cancer - nab-PTX vs DTX Phase III

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017487

Enrollment

500

Registered

2015-05-22

Start date

2015-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

A: Docetaxel (60 mg/m2) given on day 1 every 3 weeks B: Nab-paclitaxel (100mg/m2) given on day 1,8,15 every 3 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically or cytologically confirmed diagnosis of NSCLC 2) Previously treated non-small cell lung cancer with stage IIIB, IV or recurrent disease 3) Patient previously treated with at least two regimens of chemotherapy *Recurrence within a year or less from the day adjuvant chemotherapy finished is considered a previous treatment. 4) Age of 20 years or older 5) Performance Status (ECOG) 0-1 6) Tumor has the evaluable lesion

Exclusion criteria

Exclusion criteria: 1) Treatment history of taxanes 2) Synchronous or metachronous active double malignancies 3) Infectious disease requiring systemic treatment 4) Fever of 38 degrees centigrade or higher 5) Psychotic disorder

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Progression-free survival, response rate, toxicity, QOL	—

Countries

Japan

Contacts

Public ContactYasuto Yoneshima

Kyushu University Hospital Department of Respiratory Disease

y.yoneshima@gmail.com092-642-5378

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026